Home Health AstraZeneca Reports Mixed Lung Cancer Trial Results
Health

AstraZeneca Reports Mixed Lung Cancer Trial Results

Key Points

Aug 17th, 2026 AstraZeneca Reports Mixed Lung Cancer Trial Results AstraZeneca is stopping a clinical trial of the experimental drug volrustomig as it didn’t look set to help fight lung cancer better than existing therapies. The company had two separate late-stage trial successes that strengthen key cancer franchises, including one where patients with non-small cell lung cancer received Tagrisso in combination with Orpathys. Bloomberg Intelligence's Sam Fazeli has more on "Bloomberg Open...

Aug 17th, 2026 AstraZeneca Reports Mixed Lung Cancer Trial Results AstraZeneca is stopping a clinical trial of the experimental drug volrustomig as it didn’t look set to help fight lung cancer better than existing therapies. The company had two separate late-stage trial successes that strengthen key cancer franchises, including one where patients with non-small cell lung cancer received Tagrisso in combination with Orpathys. Bloomberg Intelligence's Sam Fazeli has more on "Bloomberg Open Interest."
AstraZeneca Reports (ORG) AstraZeneca (ORG) Tagrisso (ORG) Orpathys (ORG) Bloomberg Intelligence's (ORG) Sam Fazeli (PERSON)
Originally published by Bloomberg Markets Read original →